Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Radiotherapy for Graves' ophthalmopathy].

T Kuhnt1, A C Müller, M Janich

  • 1Martin-Luther-Universität Halle-Wittenberg, Universitätsklinik und Poliklinik für Strahlentherapie. thomas.kuhnt@medizin.uni-halle.de

Klinische Monatsblatter Fur Augenheilkunde
|November 25, 2004
PubMed
Summary

Radiotherapy is an effective treatment for Graves' ophthalmopathy (GO), particularly in active phases. Current research explores optimal dosages and fractionation, with ongoing multi-centric studies aiming to improve therapeutic outcomes for this autoimmune thyroid disorder.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

DEGRO statement on the FAST-Forward trial: 10-year data of ultrahypofractionated radiation therapy for breast cancer.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2025
Same author

Short-term survivors with brain metastases have modest benefits from focal and systemic therapies and remain frequent despite improving treatment landscape.

Clinical and translational radiation oncology·2025
Same author

Implant-based reconstruction and adjuvant radiotherapy in breast cancer patients-current status and DEGRO recommendations.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2025
Same author

Comparing the quality of care in physician networks to usual care for elderly patients in three German regions: a quasi-experimental cohort study.

Public health·2024
Same author

[Skull base surgery in the German DRG system-New categorization of important procedures].

HNO·2023
Same author

Long-term survival in patients with brain metastases-clinical characterization of a rare scenario.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2023

Area of Science:

  • Ophthalmology
  • Endocrinology
  • Radiation Oncology

Background:

  • Graves' ophthalmopathy (GO) is the most common extrathyroidal manifestation of Graves' disease, an autoimmune thyroid disorder.
  • The precise pathogenesis of GO remains unclear, and therapies for moderate to severe cases yield suboptimal results (40-70% improvement).
  • Radiotherapy is a controversial yet established treatment option for moderate GO (NO SPECS classes 2-5), especially with diplopia, in German-speaking countries.

Purpose of the Study:

  • To describe the sequences, dosages, fractionation schemes, risks, and side effects of radiotherapy for Graves' ophthalmopathy.
  • To assess the effectiveness and safety of radiotherapy as a treatment modality for GO.
  • To highlight the importance of patient selection and the optimal timing of radiotherapy during the active phase of GO.

Related Experiment Videos

Main Methods:

  • Review of radiotherapy protocols, including sequences, dosages (e.g., 16-20 Gy in 8-10 fractions), and fractionation schemes.
  • Analysis of retrospective data and results from a national survey of German radiotherapy departments (DEGRO working group).
  • Inclusion of findings from two prospective German studies comparing different radiotherapy regimens (short, low-dose vs. standard 20 Gy).

Main Results:

  • Radiotherapy is considered an effective and safe method for treating Graves' ophthalmopathy.
  • Standard protocols in German radiooncology departments involve 16-20 Gy delivered in 8-10 fractions.
  • Recent studies suggest equivalence in effectiveness between short, low-dose regimens and standard 20 Gy therapy, indicating no definitive recommendation on dosage or fractionation yet.

Conclusions:

  • Radiotherapy is an effective and safe treatment for Graves' ophthalmopathy, particularly when administered during the early, active phase.
  • Optimal patient selection is crucial for successful radiotherapy outcomes.
  • Further multi-centric investigations, like those by the European Group on Graves' Orbitopathy Experience (EUGOGO), are needed to refine treatment strategies and improve therapeutic results.